Quantification in patient urine samples of felbamate and three metabolites: Acid carbamate and two mercapturic acids

Epilepsia

Volumn 40, Issue 6, 1999, Pages 769-776

  Thompson, Charles D ^a   Barthen, Mary T ^a   Hopper, Darrin W ^a   Miller, Thomas A ^a   Quigg, Mark ^b   Hudspeth, Candice ^b   Montouris, Georgia ^c   Marsh, LaDonna ^c   Perhach, James L ^d   Sofia, R Duane ^d   Macdonald, Timothy L ^a,e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Epi Care Center   (United States)

^d Wallace Laboratories   (United States)

^e Chemistry Department   (United States)

Author keywords

Atropaldehyde; Felbamate; Mercapturate; Metabolite; Toxicity

Indexed keywords

3 CARBAMOYL 2 PHENYLPROPIONALDEHYDE; ACETYLCYSTEINE; ACETYLCYSTEINE DERIVATIVE; CARBAMIC ACID DERIVATIVE; FELBAMATE; N D3 ACETYL S (2 PHENYLPROPAN 3 OLYL)CYSTEINE; N D3 ACETYL S CYSTEINYL 2 PHENYLPROPANOIC ACID; UNCLASSIFIED DRUG;

ACCURACY; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; REACTION ANALYSIS; URINALYSIS; VALIDATION PROCESS;

ACETYLCYSTEINE; ALDEHYDES; ANIMALS; ANTICONVULSANTS; CARBAMATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPILEPSY; HUMANS; MASS SPECTROMETRY; PROPYLENE GLYCOLS; RADIOISOTOPE DILUTION TECHNIQUE; RATS;

EID: 0033012622     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00777.x     Document Type: Article

References (19)

1. Fraser AD. New drugs for the treatment of epilepsy. Clin Biochem 1996;29:97-110.
2. Brodie MJ, Pellock JM. Diagnosis and treatment of epilepsy in children and adolescents. Drugs 1996;51:399-414.
3. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs, Clin Pharmacokinet 1993;24:441-52.
4. Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986;27:27-34.
5. Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995;45:456-60.
6. O'Neil MG, Perdun CS, Wilson MD, McGown ST, Patel S. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996; 46:1457-9.
7. Nightingale SL. From the Food and Drag Administration: recommendation to immediately withdraw patients from treatment with felbamate. JAMA 1994;272:995.
8. Thompson CD, Kinter MT, Macdonald TL. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. Chem Res Toxicol 1996;9:1225-9.
9. Thompson CD, Gulden PH, Macdonald TL. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chem Res Toxicol 1997;10:457-62.
10. Adusumalli VE, Choi YM, Romanyshyn LA, et al. Isolation and identification of 3-carbamoyloxy-2-phenylpropionic acid as a major human urinary metabolite of felbamate. Drug Metab Dispos 1993;21:710-6.
11. Choi YM, Kucharczyk N, Sofia RD. Synthesis of deuteriumlabeled felbamate from diethyl phenylmalonate. J Labelled Comp Radiopharmacol 1986;23:785-9.
12. Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokin 1982;7:93-107.
13. Matthews AM, Roberts DW, Hinson JA, Pumford NR. Acetaminophen-induced hepatotoxicity. Analysis of total covalent binding vs. specific binding to cysteine. Drug Metab Dispos 1996;24: 1192-6.
14. Nelson SD. Metabolic activation and drug toxicity. J Med Chem 1982;25:753-65.
15. Harrison AC, Kitteringham NR, Clarke JB, Park BK. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem Pharmacol 1992;43:1421-30.
16. Bourdi M, Chen W, Peter RM, et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996;9:1159-66.
17. Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996;50:573-82.
18. Thompson CD, Vachaspati PR, Kolis SP, et al. A proposed mechanism for p-aminoclonidine allergenicity based on its relative oxidative lability. Chem Res Toxicol 1997;10:1032-6.
19. Uetrecht JP. Current trends in drug-induced autoimmunity. Toxicology 1997;119:37-43.